A major challenge in manufacturing adherent cells for advanced therapies is producing the large quantities of cells needed in a cost-effective manner. Corning has developed a novel fixed bed bioreactor platform that is designed to deliver: -Significant surface area intensification and high-yield bioproduction capability. -Scalability for adherent cell culture expansion from research to production(1 m2..